Corcept Therapeutics Incorporated Common Stock (CORT)
Stock · NASDAQ · Health Care
$109.89as of 10/16/2026
Price chart
Active signals
CORT Signal Track Record
How signals performed across all stocks →What CORT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -0.4% | 45% | September 18, 2026 |
| Bollinger Band Breakout | 27 | +4.8% | 63% | September 24, 2026 |
| Bollinger Band BreakdownActive now | 14 | -0.2% | 50% | February 19, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +16.1% | 62% | May 21, 2026 |
| Any 20-session window (baseline) | +3.6% | 61% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus o…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 730
- Website
- www.corcept.com/
Fundamentals
- 1-day range
- $109.23$113.64
- Market cap
- $11.67B
- P/E (trailing)
- 225.11
- P/E (forward)
- 24.80
- EPS (trailing)
- $0.43
- Dividend yield
- —
- Beta
- 0.52
- Avg. volume
- 1.25M
How Corcept Therapeutics Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Corcept Therapeutics Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- CORTCorcept Therapeutics Incorporated Common Stock$110.16▼ 2.83%Market cap $11.67BP/E 225.11$28.66$126.38
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$449.74▼ 2.19%Market cap $11.79BP/E —$393.61$615
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
- ELANElanco Animal Health Incorporated Common Stock$23.55▲ 0.04%Market cap $12.09BP/E —$19.4$27.98
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CORT Corcept Therapeutics Incorporated Common Stock | $11.67B | 225.11 | $110.16 | ▼ 2.83% | $28.66$126.38 |
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.79B | — | $449.74 | ▼ 2.19% | $393.61$615 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $23.55 | ▲ 0.04% | $19.4$27.98 |
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings GrowthYahoo · 10/6/2026
- 3 Reasons to Sell CORT and 1 Stock to Buy InsteadYahoo · 10/6/2026
- The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health CompaniesYahoo · 10/5/2026
- 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeYahoo · 10/2/2026
- Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?Yahoo · 9/29/2026
- Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)Yahoo · 9/25/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 9/25/2026
- Corcept Announces Planned Leadership TransitionYahoo · 9/23/2026
Insider Activity
Insider Actions →- Vieira Roberto Wandenkolk · October 2, 2026 · Option Exercise8.3K @ $21.63
- Vieira Roberto Wandenkolk · October 2, 2026 · Sale5.1K @ $116.59
- Vieira Roberto Wandenkolk · October 2, 2026 · Sale2.1K @ $115.73
- Vieira Roberto Wandenkolk · October 2, 2026 · Sale1.1K @ $114.52
- Joseph Douglas Lyon · October 2, 2026 · Option Exercise5.8K @ $19.26
- Joseph Douglas Lyon · October 2, 2026 · Option Exercise3.4K @ $13.56
- Joseph Douglas Lyon · October 2, 2026 · Sale4.7K @ $116.54
- Joseph Douglas Lyon · October 2, 2026 · Sale4.4K @ $115.7
- Sean Maduck · October 2, 2026 · Option Exercise24.6K @ $8.27
- Sean Maduck · October 2, 2026 · Sale8.7K @ $116.55
- Sean Maduck · October 2, 2026 · Sale15.8K @ $116.12
- Joseph Douglas Lyon · October 1, 2026 · Option Exercise810 @ $13.56
- Joseph Douglas Lyon · October 1, 2026 · Sale810 @ $115.4
- Sean Maduck · October 1, 2026 · Option Exercise413 @ $8.27
- Sean Maduck · October 1, 2026 · Sale413 @ $115.54
Institutional Ownership
March 31, 2026
- Total shares held
- 76.50M
- Total value held
- $2.73B
- Institutional holders
- 341
- Unknown12.15M
- Unknown7.61M
- Unknown5.68M
- Unknown4.08M
- Unknown3.98M
- Unknown3.20M
- Unknown3.19M
- Unknown2.71M
- Unknown2.17M
- Unknown1.55M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CORT Featured in Low-Beta Healthcare Stock List
Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.
CORT Featured in Low-Beta Healthcare Stock List. Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.